angiotensin

Following the publication of full data from a late-stage study of La Jolla Pharmaceutical Company (NASDAQ: LJPC)'s LPJC-501, a proprietary formulation of angiotensin II, SunTrust Robinson Humphrey said it expects approval in 2018. The Study And The Results The full data from the Phase III study,...